A live webcast of Mesoblast's presentation can be accessed via either http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=19955 or http://investorsmedia.mesoblast.com
The archived webcast will be available in the Events and Presentations section of the Company's website via www.mesoblast.com.
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a global leader in cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncology/hematology conditions.
For further information, please contact:
Julie Meldrum
Global Head of Corporate Communications Mesoblast Limited
T: +61 3 9639 6036
E: julie.meldrum@mesoblast.com
Mesoblast Limited issued this content on 2016-01-08 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-07 22:53:05 UTC
Original Document: http://phx.corporate-ir.net/external.file?t=2&item=o8hHt16027g9XhJTr8+weNRYaV9bFc2rMd0Q/AXw4zvPVBZa1YJT4+3IhwrLS0JHtNaGMuN2rZLaBydpz7QzLZZwS/5mR+U5WURZ3kMblPrsqxbTDsxYxL/RcYfIgPbMKqBN40hJm4MlP5kPoYBB/A==&cb=635878024720340066